Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02777086 · ClinicalTrials.gov registry record · NA
Sustainable HIV Risk Reduction Strategies for Probationers
A NA study, sponsored by Texas Christian University.
- Completed
- Registry status
- NA
- Development phase
- 511
- Enrollment target
NCT02777086: Completed NA study, sponsored by Texas Christian University.
NCT02777086 is a NA study that has completed, run by Texas Christian University. The registered enrollment target is 511 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02777086, a NA study, has completed, sponsored by Texas Christian University.
- COMPLETED
- Registry status
- NA
- Development phase
- 511 participants
- Enrollment target
Study Summary
The purpose of the Texas Christian University (TCU) Disease Risk Reduction (DRR2) Project is to develop and test a self-administered tablet computer app, StaySafe, for probationers under community supervision that is designed to improve decision-making skills around health risk behaviors, especially involving HIV and hepatitis B \& C risks. StaySafe utilizes materials and concepts adapted from an earlier, group-based curriculum, WaySafe, designed to increase positive decision-making skills for offenders in the last phase of their prison-based substance abuse treatment before transitioning back to the community.
Primary Outcome
Questionnaire measure of knowledge, confidence \& motivation around HIV knowledge. Values range from 10 to 50 with higher scores indicating higher knowledge, confidence \& motivation.
Interventions
- BEHAVIORAL StaySafe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 511 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2020-03-31 |
| Phase | NA |
What the finished NCT02777086 record still lists
NCT02777086 is an interventional study that assigns participants to a tested intervention. The registered 511 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 1 intervention - of which StaySafe is the first listed.
NCT02777086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02777086 about?
NCT02777086 is a clinical study titled "Sustainable HIV Risk Reduction Strategies for Probationers". The purpose of the Texas Christian University (TCU) Disease Risk Reduction (DRR2) Project is to develop and test a self-administered tablet computer app, StaySafe, for probationers under community supervision that is designed to improve decision-making skills around health risk behaviors, especially...
What is the current status of trial NCT02777086?
This trial is currently completed. It is a NA study. The enrollment target is 511 participants. The study started on 2015-09-30. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02777086?
The interventions under investigation include: StaySafe (BEHAVIORAL).
Who is sponsoring clinical trial NCT02777086?
This trial is sponsored by Texas Christian University, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02777086's enrollment target sits among peer trials
511 192nd of 2000 higher than 1,809 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
- NCT05337410 · 512 participants · NA
YES: Innovative Discussion for Engagement, Achievement, and Service
- NCT06096259 · 512 participants · Phase 2
Preventing Injured Knees From osteoArthritis: Severity Outcomes
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI